相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of Low-Magnitude Whole-Body Vibration Combined with Alendronate in Ovariectomized Rats: A Random Controlled Osteoporosis Prevention Study
Guo-Xian Chen et al.
PLOS ONE (2014)
Standardized Nomenclature, Symbols, and Units for Bone Histomorphometry: A 2012 Update of the Report of the ASBMR Histomorphometry Nomenclature Committee
David W. Dempster et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis
Steve Arns et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
The role of the EP receptors for prostaglandin E2 in skin and skin cancer
J. E. Rundhaug et al.
CANCER AND METASTASIS REVIEWS (2011)
International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, Updating 15 Years of Progress
D. F. Woodward et al.
PHARMACOLOGICAL REVIEWS (2011)
Bone marrow cells are targets for the anabolic actions of prostaglandin E2 on bone: Induction of a transition from nonadherent to adherent osteoblast precursors
Andrew Scutt et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats
J. Gregory Seedor et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Effects of combined prostaglandin and alendronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized rats
D.B. Lauritzen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Continuous PGE2 leads to net bone loss while intermittent PGE2 leads to net bone gain in lumbar vertebral bodies of adult female rats
X. Y. Tian et al.
BONE (2008)
Normal Bone Anatomy and Physiology
Bart Clarke
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
R. G. G. Russell et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Prostaglandin E2 receptors in bone formation
M. Li et al.
INTERNATIONAL ORTHOPAEDICS (2007)
Skeletal actions of intermittent parathyroid hormone: Effects on bone remodelling and structure
Juliet E. Compston
BONE (2007)
Bisphosphonates: Mode of action and pharmacology
R. Graham G. Russell
PEDIATRICS (2007)
Prostaglandin E2 (PGE2) increases the number of rat bone marrow osteogenic stromal cells (BMSC) via binding the EP4 receptor, activating sphingosine kinase and inhibiting caspase activity
M. Weinreb et al.
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2006)
A nonprostanoid EP4 receptor selective prostaglandin E2 agonist restores bone mass and strength in aged, ovariectomized rats
HZ Ke et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis
DM Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Osteopenia and impaired fracture healing in aged EP4 receptor knockout mice
M Li et al.
BONE (2005)
Osteoclast-derived activity in the coupling of bone formation to resorption
TJ Martin et al.
TRENDS IN MOLECULAR MEDICINE (2005)
Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose
JL Vahle et al.
TOXICOLOGIC PATHOLOGY (2004)
A selective EP4 receptor antagonist abrogates the stimulation of osteoblast recruitment from bone marrow stromal cells by prostaglandin E-2 in vivo and in vitro
D Shamir et al.
BONE (2004)
EP2 and EP4 prostanoid receptor signaling
JW Regan
LIFE SCIENCES (2003)
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
DM Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The effects of parathyroid hormone, alendronate, or both in men with osteoporosis
JS Finkelstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Discovery of a potent and selective agonist of the prostaglandin EP4 receptor
X Billot et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety
JL Vahle et al.
TOXICOLOGIC PATHOLOGY (2002)
Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation
K Yoshida et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Effects of selective prostaglandin EP4 receptor antagonist on osteoclast formation and bone resorption in vitro
M Tomita et al.
BONE (2002)
Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis
JM Halasy-Nagy et al.
BONE (2001)
Expression of the prostaglandin E2 (PGE2) receptor subtype EP4 and its regulation by PGE2 in osteoblastic cell lines and adult rat bone tissue
M Weinreb et al.
BONE (2001)
Characterization of the prostaglandin receptors in human osteoblasts in culture
P Sarrazin et al.
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2001)
Systemic prostaglandin E-2 increases cancellous bone formation and mass in aging rats and stimulates their bone marrow osteogenic capacity in vivo and in vitro
S Keila et al.
JOURNAL OF ENDOCRINOLOGY (2001)
Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys
DB Burr et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2001)
Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib
T Mashiba et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
Prostaglandin E2 directly inhibits bone-resorbing activity of isolated mature osteoclasts mainly through the EP4 receptor
M Mano et al.
CALCIFIED TISSUE INTERNATIONAL (2000)
Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice
C Miyaura et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
